Ticker

AIA Group Ltd lowered its stake in Merck and Co., Inc. (NYSE: MRK) by 1.7% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 375,724 shares of the company's stock after selling 6,570 shares during the period. Merck and Co., Inc. makes up

Allspring Global Investments Holdings LLC reduced its position in shares of Merck and Co., Inc. (NYSE: MRK) by 25.5% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 672,535 shares of the company's stock after selling 229,771 shares during the

Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. Company's oncology pipeline advances with FDA acceptance of four regulatory filings, including ifinatamab deruxtecan, and strategic acquisitions like Terns to counter KEYTRUDA's 2028 patent expiry. LIPFENDRA targets statin-treated patients needing…

Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.

The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.